ERJ Open Research最新文献

{"title":"The addition of radial endobronchial ultrasound to electromagnetic navigation bronchoscopy: the NEBULA study - a randomised controlled trial.","authors":"Amanda Dandanell Juul, Arman Arshad, Alice V Christophersen, Pernille Kristiansen, Alexis Pulga, Rana Bibi, Torben Riis Rasmussen, Ole Hilberg, Nicoline M Andersen, Christian B Laursen","doi":"10.1183/23120541.01494-2025","DOIUrl":"10.1183/23120541.01494-2025","url":null,"abstract":"<p><strong>Background: </strong>Bronchoscopic biopsies are a valuable tool for diagnosing small peripheral lung lesions suspected of cancer. Electromagnetic navigation bronchoscopy (ENB) has been developed to guide the bronchoscopist to the lesion and radial endobronchial ultrasound (rEBUS) to confirm the presence lesion once reached. The combination of modalities might improve the diagnostic yield; however, only a few studies with diverting results have been published. The objective of the present study was to investigate whether the combination of rEBUS and ENB is superior to ENB alone for diagnosing peripheral lung lesions suspected of lung cancer in a pragmatic study setting representing the daily clinical practices and challenges.</p><p><strong>Methods: </strong>The study was conducted according to CONSORT guidelines. All patients were randomised for either ENB or ENB+rEBUS. The reference test was either a final histopathologic diagnosis or determined by 6 months of computed tomography surveillance. Analyses were performed using intention-to-treat, with only procedures with a definitive diagnosis categorised as \"diagnostic\".</p><p><strong>Results: </strong>Of 200 patients included from four centres, 183 were randomised and included in the final analyses. There was no difference in diagnostic yield between the two groups (43.8% <i>versus</i> 45.7%), nor did we find any difference in malignant yield or adverse events.</p><p><strong>Conclusion: </strong>ENB+rEBUS is a safe and well-tolerated procedure, but not superior to ENB alone.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13402982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pleuroparenchymal fibroelastosis-like findings identify an idiopathic pulmonary fibrosis subgroup with shortened telomeres and poor prognosis.","authors":"Ryota Otoshi, Hideya Kitamura, Takashi Niwa, Kota Murohashi, Tsuneyuki Oda, Tomohisa Baba, Eri Hagiwara, Tae Iwasawa, Tamiko Takemura, Koji Okudela, Yosui Nojima, Yoshinori Nakamura, Kenji Mizuguchi, Yayoi Natsume-Kitatani, Takashi Ogura","doi":"10.1183/23120541.01619-2025","DOIUrl":"10.1183/23120541.01619-2025","url":null,"abstract":"<p><strong>Background: </strong>Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease (ILD) with poor prognosis. Radiological pleuroparenchymal fibroelastosis (PPFE)-like findings, characterised by upper-lobe subpleural fibrosis, have been associated with worse outcome in IPF. While short leukocyte telomere length (LTL) is a recognised prognostic factor, its relationship with PPFE-like findings remains unclear.</p><p><strong>Methods: </strong>We conducted a secondary analysis of an ongoing ILD cohort. IPF patients who underwent LTL measurement by quantitative PCR were classified into those with PPFE-like findings on high-resolution computed tomography (IPF/PPFE group) and those without such findings (IPF/usual interstitial pneumonia (UIP) group). Clinical characteristics, pulmonary function, telomere length and outcomes were compared. Age-adjusted LTL was evaluated using healthy controls. Prognostic factors were analysed using Cox regression.</p><p><strong>Results: </strong>Among 179 IPF patients, 29 (16%) were assigned to the IPF/PPFE group. Compared to the IPF/UIP group (n=150), the IPF/PPFE group had lower body mass index and forced vital capacity, and significantly shorter LTL (p=0.002), with more patients below the 10th percentile of healthy controls (37.9% <i>versus</i> 12.0%). The IPF/PPFE group showed greater respiratory functional decline and higher mortality (65.5% <i>versus</i> 25.3%, p<0.001). In survival analysis, both PPFE-like findings and shortened LTL predicted worse outcomes; however, only PPFE-like findings remained independently associated with mortality in multivariate analysis.</p><p><strong>Conclusions: </strong>IPF patients with PPFE-like findings constitute a distinct high-risk phenotype with shorter telomeres, accelerated progression, and poor prognosis. These findings highlight the clinical importance of recognising PPFE-like changes and telomere biology in IPF for risk stratification and emphasise the need for close monitoring and early intervention.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13402969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of obstructive sleep apnoea with exercise capacity and mortality in a population-based study: results of SHIP-TREND.","authors":"Anne Obst, Beate Stubbe, Sabine Kaczmarek, Amro Daboul, Markus Krüger, Henry Völzke, Thomas Penzel, Ingo Fietze, Ralf Ewert","doi":"10.1183/23120541.01520-2025","DOIUrl":"10.1183/23120541.01520-2025","url":null,"abstract":"<p><strong>Study objectives: </strong>Sleep and physical fitness are interrelated, with cardiovascular risk factors potentially influencing this relationship. Sleep disturbances and reduced exercise capacity are linked to higher mortality. This study examined associations between sleep characteristics, cardiopulmonary exercise testing (CPET) measures and all-cause mortality, and assessed whether reduced exercise capacity mediates the link between impaired sleep and mortality.</p><p><strong>Methods: </strong>We analysed 1001 participants from the population-based SHIP-TREND cohort (2008-2012) who underwent single-night polysomnography and symptom-limited CPET. Associations between sleep and CPET measures, as well as mortality, were assessed using multivariable linear and Cox regression models.</p><p><strong>Results: </strong>The mean age of participants was 54 (range 44-63) years; 47.1% were women. The apnoea-hypopnoea index (AHI) was 4.9 (95% CI 1.4-13.7) events·h^-1 and higher in men (7.9, 95% CI 2.6-18.8) than in women (2.6, 95% CI 0.7-9.2; p<0.001). Peak oxygen uptake (<i>V</i>'_O₂ _peak) was lower in women (22 (95% CI 18-25) mL·min^-1·kg^-1) than in men (27 (95% 22-32) mL·min^-1·kg^-1; p<0.001). Higher AHI and oxygen desaturation index were inversely associated with <i>V</i>'_O₂ _peak. Over a median 10.3-year follow-up, 73 deaths occurred. AHI was significantly associated with all-cause mortality across models (hazard ratio 1.31-1.72). Mediation analysis demonstrated a significant direct effect, whereas the indirect effect <i>via V</i>'_O₂ _peak was not statistically significant.</p><p><strong>Conclusions: </strong>In the SHIP-TREND-0 cohort, elevated AHI is associated with reduced <i>V</i>'_O₂ _peak and increased all-cause mortality. Mediation analysis suggested a possible, but not statistically significant, contribution of impaired cardiopulmonary fitness to the relationship between sleep apnoea and mortality, highlighting a potential role of fitness that warrants further investigation.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13402971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between plasma favipiravir concentrations and clinical outcomes in COVID-19.","authors":"Rebecca E Wawman, Pallav L Shah, Marta Boffito, James Tonkin, Francesca Conway, Anand Tana, Breno R Santos, Beatriz Grinsztejn, Brenda Crabtree Ramírez, Henry Pertinez, Andrew Owen, Paul Curley, Usman Arshad, Helen Cox, Mark R Johnson, Anton Pozniak, Michael Pelly, Christopher M Orton, Pankaj K Bhavsar","doi":"10.1183/23120541.01560-2025","DOIUrl":"10.1183/23120541.01560-2025","url":null,"abstract":"<p><strong>Background: </strong>Favipiravir has shown efficacy against SARS-CoV-2 in patients <60 years old, but data linking plasma concentrations to clinical outcomes are limited. This study investigated whether favipiravir plasma concentrations influence clinical efficacy and outcomes in patients hospitalised with COVID-19. The main research question was, How can antiviral dosing strategies be optimised to improve pandemic preparedness and treatment efficacy?</p><p><strong>Methods: </strong>Adult participants were drawn from the PIONEER trial, in which patients received oral favipiravir (1800 mg twice daily for 1 day, then 800 mg twice daily for 9 days) plus standard care. This analysis included patients with confirmed COVID-19 and ≥75% study adherence. Samples were collected between days 5 and 10 post-treatment initiation. The primary outcome was time to clinical improvement. Secondary outcomes included achievement of clinical improvement and mortality risk.</p><p><strong>Results: </strong>Out of 140 patients (50% male; mean±sd age 59.5±14.8 years), target plasma concentrations were reached in 29 (21%). Mean time to improvement was 7.7±5.9 days in target achievers <i>versus</i> 9.1±7.2 days in non-achievers (p=0.26). The target was more often achieved in female (34%) than male (7%) participants (p=0.0002). Plasma concentration inversely correlated with body mass index (r= -0.4, p<0.0001), and with lower body mass index in achievers (26.0±5.1 kg·m^-2 <i>versus</i> 30.5±6.9 kg·m^-2, p=0.003). Alkaline phosphatase and alanine aminotransferase levels were also lower in achievers (p=0.004 and p=0.02, respectively).</p><p><strong>Conclusion: </strong>Most patients did not reach target favipiravir levels. Concentrations were influenced by sex, body mass index and liver function, confirming the need for pharmacokinetically guided dosing and therapeutic monitoring to optimise antiviral efficacy in future pandemic responses.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moderate hypoxaemia and cognitive impairment in individuals with cigarette smoke exposure.","authors":"T Mitchell Mazza, Chloe Hill, Dan Pergel, Devin J Burke, Katherine A Pratte, Russell P Bowler, Craig P Hersh, Stephen J Glatt, Jonathan L Hess, Karin F Hoth, Auyon J Ghosh","doi":"10.1183/23120541.01562-2025","DOIUrl":"10.1183/23120541.01562-2025","url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment (CI) is among the extrapulmonary comorbidities that are increasingly recognised in individuals with COPD and a history of cigarette smoke exposure. While severe hypoxaemia is a well-established risk factor for CI, the role of moderate hypoxaemia (peripheral oxygen saturation (<i>S</i> _pO₂ ) 89-93%) is unknown.</p><p><strong>Methods: </strong>We evaluated the association between moderate hypoxaemia, assessed by pulse oximetry, and CI in participants from the Genetic epidemiology of COPD (COPDGene) study who completed the Phase 3 (10-year follow-up) visit. We performed mediation analysis of moderate hypoxaemia on the association between COPD and CI. We tested for differences in proteomic biomarkers of cerebral hypoxia and performed differential gene expression and pathway enrichment analyses to compare individuals with moderate hypoxaemia with those with CI.</p><p><strong>Findings: </strong>We found that moderate hypoxaemia at the 5-year follow-up visit, but not at the baseline visit, is associated with CI as assessed at the 10-year follow-up visit (OR 1.49, 95% confidence interval 1.10-1.99). In addition, moderate hypoxaemia significantly mediates the association between COPD and CI (average causal-mediated effect, 27.3%; p<0.001). Out of 38 proteins previously associated with cerebral hypoxia, 13 were significantly associated with moderate hypoxaemia.</p><p><strong>Interpretation: </strong>Our study establishes moderate hypoxaemia as an important risk factor for CI in individuals with a history of cigarette smoke exposure and as a mediator of the risk of CI in individuals with COPD. We also identify multi-omic biomarkers that better characterise the biological pathways underlying the association between moderate hypoxaemia and CI. Future studies are needed to identify individuals with moderate hypoxaemia who are at the highest risk of CI.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13402997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peri-transplant frailty changes impact survival in interstitial lung diseases.","authors":"Stefan Kuhnert, Sabina Guler, Luise Wilke, Janine Sommerlad, Silke Tello, Anita Windhorst, Andreas Guenther, Matthias Hecker, Ekaterina Krauss","doi":"10.1183/23120541.01565-2025","DOIUrl":"10.1183/23120541.01565-2025","url":null,"abstract":"<p><strong>Background: </strong>Frailty is a dynamic state of vulnerability resulting from progressive functional decline and multimorbidity in patients with interstitial lung disease (ILD). The effect of lung transplantation (LTx) on frailty and its prognostic significance remains insufficiently understood.</p><p><strong>Methods: </strong>This single-centre cohort study aimed to characterise peri-transplant frailty trajectories, measured by the clinical frailty scale (CFS), and determine their impact on long-term survival in patients with ILD undergoing LTx. CFS was assessed pre-operatively, at 4-months and 5-years post-transplant. Patients were categorised as fit (CFS 1-3), vulnerable (CFS 4) or frail (CFS 5-9). Frailty change (ΔCFS) was classified as improved (ΔCFS ≤-1), unchanged (ΔCFS 0) or worsened (ΔCFS ≥+1). Survival was analysed using Kaplan-Meier estimates and Cox proportional hazards models.</p><p><strong>Results: </strong>The proportion of fit patients increased from 22.2% before to 87.5% 4 months and 75.0% 5 years post-transplant. Frailty improved in 93.1%, remained unchanged in 2.8% and worsened in 4.1% of patients. Median ΔCFS was -3 in frail, -1 in vulnerable and 0 in pre-LTx fit patients. Prolonged intensive care unit/hospital stay/ventilation was associated with reduced CFS recovery. Each one-point increase in ΔCFS was associated with a 1.76-fold higher mortality hazard (95% CI 1.34-2.31, p<0.001). Compared to those with improvement, patients with worsened frailty had a 43.9-fold higher mortality hazard (95% CI 10.1-173.2, p<0.001).</p><p><strong>Conclusions: </strong>Peri-transplant CFS trajectory is associated with long-term survival in ILD, underscoring frailty as a modifiable risk factor and highlighting the need for systematic assessment and targeted interventions to optimise outcomes throughout the transplant course.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13383198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiographic severity and treatment optimisation in <i>Mycobacterium avium</i> complex pulmonary disease.","authors":"Youngchan Cho, Jiin Bae, Joong-Yub Kim, Jae-Joon Yim, Soon Ho Yoon, Nakwon Kwak","doi":"10.1183/23120541.01355-2025","DOIUrl":"10.1183/23120541.01355-2025","url":null,"abstract":"<p><strong>Background: </strong>We developed a chest radiography (CXR) scoring system using a deep neural network to quantify the severity of <i>Mycobacterium</i> <i>avium</i> complex pulmonary disease (MAC-PD). This study aimed to stratify disease extent using CXR scores and propose treatment strategy accordingly.</p><p><strong>Methods: </strong>We analysed chest radiographs obtained at treatment initiation in patients who began therapy for MAC-PD at Seoul National University Hospital between 1 January 2011, and 31 August 2024. Patients were classified into mild or extensive disease groups based on a CXR score cut-off of 4.0. The impact of macrolide/ethambutol-based initial treatment regimens, alternative intensified regimens (including inhaled amikacin or clofazimine), and intensified regimens (including intravenous amikacin) on culture conversion was assessed using Cox proportional hazards models.</p><p><strong>Results: </strong>The study comprised 541 patients (299 and 242 with mild and extensive disease types, respectively). Alternative intensified regimens were used in 103 patients (19.0%), and intensified regimens were used in 25 patients (4.6%). Culture conversion was achieved in 450 patients (83.2%), with no significant differences between the mild (81.6%) and extensive (85.1%) groups (p=0.277). In mild disease, neither alternative intensified regimens (adjusted hazard ratio (aHR) 0.84, 95% confidence interval (CI) 0.60-1.19) nor intensified regimens (aHR 0.99, 95% CI 0.53-1.89) were associated with improved culture conversion. In contrast, in extensive disease, use of intensified regimens (aHR 1.90, 95% CI 1.12-3.22) was associated with a higher likelihood of culture conversion.</p><p><strong>Conclusion: </strong>CXR score-based disease stratification may guide individualised treatment strategy in patients with MAC-PD.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13383090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of sputum cytology in severe asthma: insights from a specialist centre.","authors":"Sunera Khan, Sharron Gilbey, Muna Sheego, Emily Lyng, Anita Cass, Shabnam Latif, Rebecca Taylor, Gerald Langman, Jessica Shingler, Heather Stephens, Anilkumar Pillai, Adel H Mansur","doi":"10.1183/23120541.01588-2025","DOIUrl":"10.1183/23120541.01588-2025","url":null,"abstract":"<p><p><b>Sputum cytology can be successfully implemented in routine severe asthma care, providing critical information on airway inflammation beyond blood eosinophils or <i>F</i> _ENO to guide more precise, phenotype-driven treatment decisions</b> https://bit.ly/4rhSWiP.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13383205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the small airways with tezepelumab.","authors":"Jo Vi Lim, Chris RuiWen Kuo, Rory Chan","doi":"10.1183/23120541.00223-2026","DOIUrl":"10.1183/23120541.00223-2026","url":null,"abstract":"<p><p><b>Oscillometry-defined small airway dysfunction (SAD) is prevalent in severe asthma and may improve with tezepelumab. This real-world study supports SAD as a clinically relevant, treatable trait and proposes oscillometry as a complementary assessment tool.</b> https://bit.ly/4r1sIAf.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13383089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automatic oxygen titration during exercise in pulmonary rehabilitation: a pilot trial.","authors":"Tessa Schneeberger, Inga Jarosch, Rainer Gloeckl, Daniela Kroll, Leonard Kolb, Wolfgang Hitzl, Andreas Rembert Koczulla","doi":"10.1183/23120541.01533-2025","DOIUrl":"10.1183/23120541.01533-2025","url":null,"abstract":"<p><p><b>Automatic oxygen titration resulted in similar dyspnoea and physiological responses to prescribed constant-flow oxygen during exercise in pulmonary rehabilitation and was safe, suggesting potential to improve oxygen prescription in clinical practice</b> https://bit.ly/4bPu78W.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 4","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13383199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}